(Q38123754)

29 August 2017

Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms (English)

1 reference

29 August 2017

1 reference

systolic heart failure

1 reference

1

Sohita Dhillon

1 reference

29 August 2017

language of work or name

1 reference

1 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

73

1 reference

29 August 2017

13

1 reference

29 August 2017

1451-1462

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0098-z

29 August 2017

0 references

cites work

Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone: cardiovascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

The role of the renin-angiotensin-aldosterone system in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Arterial pressure, left ventricular mass, and aldosterone in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Aldosterone and cardiovascular disease: smoke and fire

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Aldosterone induces a vascular inflammatory phenotype in the rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Effect of long-term monotherapy with the aldosterone receptor blocker eplerenone on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

The evolution of aldosterone antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Mortality in heart failure: clinical variables of prognostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Diabetes, left ventricular systolic dysfunction, and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

The risks and benefits of aldosterone antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Aldosterone receptor antagonists: effective but often forgotten

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Aldosterone antagonists--last man standing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Eplerenone: is it time to add this drug to current heart failure therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0098-Z

Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro

21 January 2018

1 reference

12 December 2020

Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.

1 reference

12 December 2020

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

1 reference

12 December 2020

High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction

1 reference

12 December 2020

Management of atrial fibrillation in patients with heart failure

1 reference

12 December 2020

Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study

1 reference

12 December 2020

Hypokalemia and sudden cardiac death.

1 reference

12 December 2020

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

12 December 2020

Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study

1 reference

12 December 2020

Positive effect of eplerenone treatment on endothelial progenitor cells in patients with chronic heart failure

1 reference

12 December 2020

Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction

1 reference

12 December 2020

Vasodilation to acetylcholine in primary and secondary forms of human hypertension

1 reference

12 December 2020

10.1007/S40265-013-0098-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1004221694

0 references

Fatcat ID

release_ewifw6hjhvfo5b6r7f6nrz2su4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ewifw6hjhvfo5b6r7f6nrz2su4

24 November 2022

mapped directly with Wikidata item

1 reference